Posted by Michael Wonder on 30 Apr 2026
Prolong’s investigational therapy for acute ischaemic stroke, PP-007, receives FDA breakthrough therapy designation
30 April 2026 - Prolong Pharmaceuticals announced today that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has received breakthrough therapy designation from the US FDA for the treatment of acute ischaemic stroke with anterior large vessel occlusion.
PP-007 is an investigational therapy designed to improve oxygen delivery in ischaemic tissue.
